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Pain is regulated endogenously through both opioid and non-opioid mechanisms. We hypothesized that two novel pain modulation
tasks, one drawing on context/expectations and one using voluntary reappraisal, would show differing levels of opioid dependence.
Specifically, we expected that naloxonewould block context-related analgesia, whereasmental imagery-based pain reappraisal would be
opioid-independent.
Adouble-blind, placebo-controlled intravenousnaloxoneversussalinecrossoverdesignwasused.Twentyhealthyvolunteerscompletedthe
two modulation tasks with acute heat stimuli calibrated to induce moderate pain. In the mental imagery task, participants imagined either a
“pleasant” or a “comparison” scenario during painful heat. In the relative relief task,moderate heat stimuli coincidedwith visual cues eliciting
relief from the expectation of intense pain, and were compared with moderate heat stimuli delivered under the expectation of non-painful
warmth.Both“pleasant imagery”and“relativerelief”conditionssignificantly improvedratingsofpain intensityandpleasantnessduringsaline
treatment. Indeed, the target stimuli in both tasks, which had been calibrated to inducemoderate pain, were rated asmildly pleasant. Further-
more, consistentlywith themainhypothesis, blocking endogenous opioid signalingwithnaloxonedidnot significantly affect imagery-induced
regulation of pain intensity or pleasantness. In contrast, the relative relief-induced pain regulation (i.e., context/expectation) was blocked by
naloxone. We conclude that endogenous opioid signaling is necessary for expectation-related relative relief analgesia, but not for pain reap-
praisalthroughmental imagery.Theseresultssupportmental imageryasapowerfulandclinicallyrelevantstrategyforregulatingpainaffectalso
in patientswhere endogenous opioidmechanismsmight be compromised.
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Introduction
Pain perception is shaped by expectations and context (Tracey,
2010; Koban et al., 2017), physiological state (Schrimpf et al.,
2015), and by voluntary regulatory techniques such as reappraisal
(Johnstone et al., 2007; Phillips et al., 2008; Wiech et al., 2008a).
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Significance Statement
Neurotransmitter systems in the human brain can be probed through antagonist drugs. Studies using the opioid antagonist
naloxone have demonstrated that the brain relies on both opioid and non-opioid mechanisms to downregulate pain. This holds
clinical relevance given altered endogenous opioid processes in many chronic pain conditions. The present study used a double-
blinded, placebo-controlled naloxone blockage of endogenous opioids in healthy humans to showdifferential opioid involvement
in two painmodulation tasks. Context/expectation-driven (relative relief-related) analgesiawas blocked by naloxone. In contrast,
pain reappraisal through mental imagery was intact despite opioid receptor blockade, suggesting opioid independence. These
results support mental imagery as a powerful, clinically relevant strategy for regulating pain as it does not rely on a functioning
opioidergic system.
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In a seminal paper, Levine et al. (1978) used high-dose naloxone
to show that placebo analgesia depends on endogenous opioids.
Naloxone at high dose provides complete blockade of -opioid
receptors (Mayberg and Frost, 1990). This opioid antagonist
would be expected to block pain modulations mediated by en-
dogenous opioid signaling in the descending pain inhibitory sys-
tem (Tracey and Mantyh, 2007; Wiech et al., 2008a). Indeed, the
finding has been replicated in several (Amanzio and Benedetti,
1999; Benedetti et al., 1999, 2007; Eippert et al., 2009; Ru¨tgen et
al., 2015, 2018), but not all subsequent placebo studies (Vase et
al., 2005; Benedetti et al., 2011) using naloxone or naltrexone in
humans. Converging evidence now points to the existence of
both opioid-dependent and opioid-independent modes of en-
dogenous analgesia in humans (Amanzio and Benedetti, 1999;
Eippert et al., 2009; Sprenger et al., 2012).
Initial studies indicate that hypnosis (Moret et al., 1991),
mindfulness meditation (Zeidan et al., 2016), and religious
prayer (Elmholdt et al., 2017) can induce analgesia largely inde-
pendently of-opioid blockade. A putative shared mechanism of
these pain modulatory techniques is voluntary, conscious reap-
praisal, which can alter the meaning of pain without targeting the
sensory aspects of the percept (Woo et al., 2015). In contrast,
opioid signaling appears to be more important for modulations
that alter pain perception without relying on voluntary reap-
praisal, such as placebo (Amanzio and Benedetti, 1999; Eippert et
al., 2009), distraction (Sprenger et al., 2012), stress-induced an-
algesia, and rTMS (Werner et al., 2015). For many types of pain
modulations, notably pain-induced analgesia [diffuse noxious
inhibitory control (DNIC)/conditioned pain modulation (CPM)],
mixed results of opioid blockade studies in humans highlight the
need for further research (Werner et al., 2015).
Here, we used high-dose naloxone in a double-blind, ran-
domized, placebo-controlled design with two novel pain modu-
lation tasks: mental imagery and relative relief. Mental imagery
involves the imagination of a more pleasant context or meaning
for the painful stimulus. It has been used to help patients cope
with pain in a variety of clinical contexts (Syrjala et al., 1995; Fors
et al., 2002; Winterowd et al., 2003; Pincus and Sheikh, 2009;
Posadzki and Ernst, 2011; Posadzki et al., 2012). The mechanisms
behind this modulation have been little studied (Berna et al.,
2012; Jensen et al., 2012), but may share some features with those
of hypnosis and mindfulness meditation. Accordingly, we hy-
pothesized that pain relief induced by mental imagery would be
unaltered by naloxone. Importantly, we contrasted the effect of
naloxone on this task with its effects on a novel, non-voluntary
pain modulation task hypothesized to recruit endogenous opi-
oids for pain relief. We previously reported reduced pain, in-
creased positive affect and activity in the periaqueductal gray
(PAG) when a context-related expectation of intense pain was
interrupted by a visual cue indicating that intense pain has been
avoided (Relative Relief cue; Leknes et al., 2013a). Thus, we make
a direct comparison of two novel pain modulation tasks with the
aim to reveal the opioid-independence of mental imagery (reap-
praisal) and the opioid dependence of relative relief (context/
expectation) analgesia in healthy humans.
Materials andMethods
Participants
Participants were recruited through advertisements on posting boards
and mailing lists at the University of Oxford, UK. They underwent a
preliminary health screening over the phone to exclude any medical
condition, chronic drug intake, or contraindications to MRI and nalox-
one. Recreational drug users and volunteers with psychiatric conditions
were excluded. Opioid intake was tested for by urine analysis on each day
of testing (none positive). Written informed consent was obtained on the
first test day. The study was approved by the Milton Keynes Research
Ethics Committee (09/H0603/17) and conformed to the guidelines of the
Declaration of Helsinki (1996). Participants were reimbursed 35 GBP per
session. The first four participants of the N  27 recruited only com-
pleted one session because their fMRI data were corrupted by an fMRI
coil dysfunction. Three further subjects did not return for a second ses-
sion after experiencing side effects attributed to naloxone. Therefore, 20
participants completed the two runs of the study (mean age: 27; range:
20 –38, 11 female), and were included in the analysis.
Procedure
The study used a within-subjects, double-blind, placebo-controlled de-
sign with two sessions separated by at least 1 d (Fig. 1). The order of the
sessions was randomized and counterbalanced across participants. The
unblinded study physicians (C.B., R.N.M.) were responsible for prepar-
ing and administering the infusions. They did not communicate with
participants until debriefing at the end of the second session, or in case of
significant side effects (N 3, participant discontinuation).
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Figure 1. Overview of study design. Participants were pseudorandomized into starting either with the naloxone or saline (placebo) session. After a brief standardized instruction, participants
practiced themental imagery tasks. Following that, the two sessions contained the same sequence: a heat pain calibration preceded the start of the infusion, which was followed by the three task
runs presented in counterbalanced order. At the end of the second session, a debriefing took place.
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After written consent, participants were given precise, standardized
instructions via a PowerPoint presentation outside of the scanner. In
both sessions, once in the scanner, yet before drug administration, heat-
pain calibration was conducted to identify two levels of pain intensity for
each participant: intense pain and moderate pain (Fig. 1). A brief practice
run took place, including the mental imagery task with heat pain and the
visual analog scale (VAS) rating system. Approximately 15 min after drug
administration started, participants completed the mental imagery task
(1 run) and the relative relief task (2 runs). Each run consisted of fourteen
5 s heat stimuli and lasted 12 min. The order of tasks and the within-run
order of stimuli were pseudorandomized and counterbalanced. Each
heat stimulus was followed by two VAS rating scales assessing stimulus
pleasantness and pain intensity (fixed order of rating scales). Tempera-
tures calibrated to yield a rating of 5/10 were used for all the moderately
painful stimuli during each session, allowing for between-task compari-
sons. Participants were blinded to this fact. Two thermodes were used to
allow shorter interstimulus intervals without representing a threat to the
skin integrity (Details in the section on heat pain stimuli).
Testing occurred in a 3T Varian scanner; EPI images were collected
during tasks (data to be reported elsewhere).
Pain modulation tasks
Mental imagery task. Participants were asked to use their imagination to
hold a mental image (i.e., retrieve perceptual information from memory
to create a new experience, allowing them to see with their mind’s eye or
feel with their mind’s skin) of a context in which heat was actually pleas-
ant. During the training phase outside of the scanner, participants were
encouraged to find a suitable scenario, and provided with examples, such
as “You are coming back to the cabin after a day out in the snow, and are
cold. You sit by the fire. Your arm stretches out and gets close to the heat.”
All participants were able to conjure up such a scenario and practiced it
first without thermal stimulation and then again inside the scanner with
thermal stimuli. Indeed, most were able to recount episodes in which
feelings of cold had rendered intense heat pleasant. Because testing oc-
curred in England during autumn/winter, many in fact imagined scenar-
ios that occurred when they were freezing within their own (typically
under-heated) lodgings. The comparison task required participants to
hold a mental image of the thermode, a clothes iron, or another noxious
heat-dissipating device being close to their skin. During the experiment,
a visual cue appearing 9 s before the heat stimulus onset signaled the condi-
tion (cued with the words: DIFFERENT/DEVICE) and instructed partici-
pants to start imagining the specific context (pseudorandomized order, 50%
chance of “pleasant” vs comparison condition; Fig. 2a). At the start of the
thermal stimulus, the screen instructed participants to feel the sensation
while continuing to hold their mental image: “FEEL (DIFFERENT/DE-
VICE)”. The visual cues consisted of black text within a purple or yellow
frame (the colors were pseudorandomized between the two conditions). The
moderate stimuli were delivered in pseudorandom order on either ther-
mode, to avoid risk of skin sensitization.
Relative relief task. The relative relief task was a modified version of the
task reported by Leknes et al., 2013a (Fig. 2b). In the “Intense” run, visual
Figure 2. Overview of the two pain modulation tasks. The temperature, number and duration of moderately painful stimuli, as well as the timing of cues, stimuli and VASs were kept the same
across tasks to facilitate comparison. To avoid skin sensitization while keeping experiments brief, two thermodes were used to deliver stimuli. A, In themental imagery task, participants imagined
scenarios inwhich themoderate heat-pain stimuli would either be pleasant (i.e., useful to alleviate hypothermia) or noxious (i.e., a standard, potentially harmful source of heat such as a pain device
or a clothes iron). Visual cues displaying the words “different” (target: pleasant imagery) or “device” (comparison imagery) were presented 9 s before the onset of each heat stimulus, instructing
participants to start imagining. B, In the relative relief task, visual cues displaying the word “Wait” were presented 9 s before each heat stimulus to induce expectation of intense pain (Intense run,
text on red background) or non-painful warm stimuli (Warm run, text displayed on a blue background). Before task onset, participants were informed that the heat stimulus following the initial
visual cue would “most likely” be the cued stimulus, the onset of which was then indicated by a cue reading “Feel” (same color background). However, when the second cue was an arrow pointing
downwardorupward, it indicated thedeliveryof amodified stimulus.Unbeknownst toparticipants, the temperatureused thenwasalways theone calibrated to inducemoderatepain. In the Intense
run, the downwardpointing arrow indicated a lower temperature stimulus than expected, thus constituting a relative relief cue. In the comparison run, the upwardpointing arrow indicated ahigher
temperature stimulus. The target and comparison stimuli were thus matched for expected and actual likelihood as well as for temperature, duration, and order of appearance.
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cues indicating an upcoming intensely painful stimulus were presented
9 s before heat pain (“Wait” on a red background). In 50% of cases, the
cue was followed by heat pain calibrated to induce intense pain (associ-
ated to a cue reading “Feel” on a red background). In the remaining 50%
of cases, a downward pointing arrow cue (relative relief cue) indicated
the occurrence of a lower temperature stimulus. The stimulus presented
with the relative relief cue was always at a temperature precalibrated to
induce moderate pain in the participant. In the Warm run, the first visual
cue indicated an upcoming warm stimulus (Wait on a blue background),
which was followed by a warm stimulus in 50% of cases (together with a
cue reading Feel on a blue background). In 50% of cases however, the
warm cue was followed by an upward pointing arrow (comparison cue),
which indicated the occurrence of a higher temperature stimulus. This
comparison moderate stimulus was identical to the relative relief stimu-
lus with regard to temperature, duration, probability, and timing within
the run.
To enhance the potency of this task, participants were led to believe
that the heat stimuli in the Intense run would be intensely painful most of
the time (and conversely, that the warm stimuli were most frequent in the
Warm run). Specifically, they were told that “In this run, the stimuli will
be mostly (intense/warm), but sometimes, the stimulus temperature will
be (lower/higher)”. Intense and warm stimuli were delivered on one
thermode, and moderate stimuli on another, to avoid risk of skin sensi-
tization.
Stimuli and outcome measures
Heat pain stimuli
Two in-house built thermal heat pain devices (thermodes) were used to
deliver 5-s-long thermal stimuli to the ventral aspect of the left forearm of
the participants, with at least 6 cm distance between them (Leknes et al.,
2013a). Two thermodes were used to alternate the delivery of the stimuli
between the two sites, allowing shorter interstimulus intervals without
representing a threat to the skin integrity. Both devices were used to
deliver moderate painful stimuli in the imagery task. To avoid sensitiza-
tion effects due to the use of a high-temperature stimulus in the relative
relief task, moderate stimuli were delivered by one thermode, whereas
the other one was used for the intense pain and warm stimuli (Leknes et
al., 2013b).
Warm stimuli were set to 40°C. The individual temperatures identified
during calibration to elicit ratings of “moderate pain” [5 on an 11-
point numerical rating scale (NRS)] were 48.1 2.3 (mean SD) across
thermodes and sessions. For intense pain (8 on the 11-point NRS) an
average temperature of 50.9  2.0 was used. Potential effects of session
and drug condition on temperatures used were addressed in a regression
analysis and significant effects led to the inclusion of temperature infor-
mation in subsequent analyses.
Poststimulus ratings
During testing, each heat stimulus was rated for pleasantness and pain
intensity on a respective VAS: “How PLEASANT was the stimulus?” with
anchors “very pleasant” to “very unpleasant”; and “How PAINFUL was
the stimulus?” anchored “not painful” and “very painful” (always in this
order).
State and trait measures
Current mood state was further assessed with six mood VASs, presented
at the beginning and the end of each run. Participants rated four separate
statements: “At this moment I feel …. sad/happy/calm/anxious” each on
a VAS with anchors “not at all” and “very much so”.
A state version (Eikemo et al., 2016) of the Snaith–Hamilton Pleasure
Scale was presented after completion of the Intense run to assess hedonic
capacity. Participants also filled in trait questionnaires including BIS/
BAS (Carver and White, 1994), STAI State and Trait Anxiety (Spiel-
berger, 1983), LOT-R (Herzberg et al., 2006), EPQ12 (Eysenck et al.,
1985), and imagery ability with the SUIS (Nelis et al., 2014; data not
reported).
Debriefing
At the completion of each run, participants responded to a series of
post-run questions from the experimenter, assessing anxiety induced by
each of the visual cues preceding heat stimuli (0 –10 NRS, both tasks);
effort and perceived success of mental imagery performance for each
imagery condition (0 –10 NRS); disappointment about the up pointing
arrow (Warm run) or relief elicited by the down pointing arrow (Intense
run; 0 –10 NRS); and positive/negative affect (5 to5 NRS) elicited by
each of the possible outcomes. These ratings were collected to supple-
ment the ratings of pleasantness and pain intensity collected during the
task.
After each test session, but before participants were removed from the
scanner, they were asked to guess whether they had received naloxone or
saline.
During final debriefing, participants were asked to estimate the fre-
quency of the intense versus moderate and warm versus moderate stimuli
in the relative relief task. At the end of the debriefing session, participants
were informed about the fact that the moderate painful stimulus was
always the same, and were informed about the order of the drug
conditions.
Urine test for opiates
Participants were screened for opiates using a urine test kit (Instalert,
Innovacon) before the start of both sessions to prevent precipitating
withdrawal (exclusion criterion). None of the tests were positive.
Drug administration
Approximately 15 min before the start of the testing, a 0.15 mg/kg bolus
of naloxone (naloxone hydrochloride, 400g/ml vials; non-proprietary,
UK) was administered intravenously through an intravenous line placed
on the right forearm. This was immediately followed by an infusion at a
rate of 0.2 mg/kg/h to keep the plasma level constant and ensure contin-
uous complete blockade of the opioid receptors (Mangold et al., 2000;
Eippert et al., 2009; Schoell et al., 2010). A matching quantity of saline
(NaCl 0.9%) was administered in the control ( placebo) condition.
Participants were informed that naloxone is a drug that interacts with
the opioid receptors, without clear effects on acute pain perception
(Eippert et al., 2009). They were also informed about possible side effects,
and that they may not be able to notice any differences between naloxone
and saline infusion. The full information about the motivation to use
naloxone during the study was presented during debriefing, in order not
to bias expectations. The study physicians (C.B. and R.N.M.) preparing
and administering the drugs did not participate in subject testing nor
communicate with participants, unless significant side effects were de-
clared, or during debriefing. The study staff conducting the testing (S.L.
and A.H.A.) was blinded to the drug assignation.
Side effects were reported at the end of each testing session on a stan-
dardized scale (Eippert et al., 2009), where each adverse effect could be
rated as “inexistent, very weak, weak, moderate, strong, very strong or
extremely strong” (0 – 6).
Statistical analysis
The main outcomes were VASs for pain intensity and stimulus pleasant-
ness of moderate heat stimuli. The stimulus pleasantness was recorded
on a bivalent scale, which was converted to a numerical rating ranging
from5 (very unpleasant) to5 (very pleasant), whereas pain intensity
VAS ratings were converted to a number between 0 and 10.
Secondary outcomes included measurements of mood, stimulus tem-
peratures, ratings of intense and warm stimuli from the Relative Relief
task, as well as post-run and debriefing ratings.
Data were analyzed with linear mixed models (LMMs) using the
mixed-effect model module (GENLINMIXED) in SPSS v24 (IBM).
Mixed effects models include both fixed and random effects and offer
superior flexibility compared with more traditional repeated measures
analyses. These models are more robust with respect to unbalanced de-
signs and missing data, allow different target distributions and the inclu-
sion of all data points without aggregation across multiple trials of one
type (Gueorguieva and Krystal, 2004).
The main analyses (one for each VAS rating type) assessed the effects of
Stimulus type, Task type, and Drug on target stimuli (“pleasant” imagery
and Intense run moderate) and the comparison moderate stimuli (“nox-
ious” imagery and the Warm run moderate) across the naloxone and
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saline conditions. To test the hypothesis that pain modulation in the
Relative Relief task would be opioid-dependent but not in the Mental
Imagery task, we assessed the three-way interaction between Drug, Stim-
ulus type, and Task type, followed by statistical assessment (planned
pairwise contrasts) of target versus comparison stimuli for each task and
each drug conditions. Any effects identified in the analysis of secondary
outcomes, which could act as potential confounders (e.g., drug effects on
mood, stimulus temperatures or intense/warm stimuli) were included as
fixed effects in the main LMMs of moderate stimuli. To adjust for depen-
dencies in the data related to individual characteristics of each partici-
pant, the main LMMs included by-subject random intercepts as well as
by-subject random slopes for drug and task. The random effects
variance-covariance matrix had a variance-components structure.
LMMs of secondary outcomes all included a fixed effect of Drug and a
random term for subject intercept. Overall, we aimed for parsimonious
models. Starting with a model that included the key design factors (Drug,
Stimulus type, and Task type) and their interactions, we then tested
whether other relevant factors would explain significant variance (i.e.,
p 0.05 and an improvement of the Bayesian information criterion2).
These additional factors were introduced to the model one by one in
order of theoretical importance: Stimulus Temperature, pain intensity
ratings of the intense heat stimulus (VASIntensity), Session, Trial Num-
ber, and Participant Gender. If a factor met the inclusion criteria, it was
kept in the model when subsequent factors were tested. When a between-
subjects factor (Gender) was kept in the model, relevant two-way inter-
actions with design factors were also tested. Multicollinearity was
assessed using collinearity diagnostics for linear regressions, and was
found to be low (variance inflation factor scores 1.3). The LMMs of
ratings of intense as well as warm stimuli used robust covariances because
data and residuals did not meet criteria for normality.
Results
Control analyses
Mood
An average mood score was computed (inverse values were used
for the items “anxious” and “sad”), and effects of Drug, Session,
Run, and Rating Time (pre- or post-run) were assessed in an
LMM. Self-reported mood was not significantly affected by
naloxone treatment (saline, 2.14  1.95; naloxone 2.24  2.0;
F(1,222) 0.29, p 0.59). Mood was marginally higher during the
second session (F(1,222) 3.8, p 0.052). Further, self-reported
mood was significantly lower before and after the intense pain
task than before and after the two other tasks (mean mood reduc-
tion 0.4 on the 11-point VAS; F(2,222) 3.3, p 0.038). Naloxone
treatment did not interact significantly with session, task, or rat-
ing time to affect mood.
Stimulus temperatures
Because stimulus temperatures were allowed to vary between ses-
sions for each individual (calibration was conducted at the onset
of each test session), effects of session and drug condition on
stimulus temperatures were assessed in an LMM with the fixed
factors Session, Drug, and Stimulus type (Moderate Thermode 1;
Moderate Thermode 2; and intense pain).
The LMM on stimulus temperatures yielded significant main
effects of Stimulus type, Session, and Drug. None of the interac-
tion terms were significant (all F values1.8, all p values0.17).
The effect of Stimulus (F(2,107)  108.6, p  0.001) reflected
higher temperatures used to elicit intense pain (50.9°C 2.0), as
well as slightly higher temperatures at thermode 2 (48.3°C 2.5)
compared with Thermode 1 (47.8°C 2.0). A small but signifi-
cant increase in temperatures used was also found for Session 2
(49.2°C 2.5) relative to Session 1 (48.8°C 2.6; F(1,107) 6.0,
p 0.016) and for the naloxone condition (49.3°C 2.4) relative
to saline (48.7°C  2.6; F(1,107)  12.2, p  0.001). The nonsig-
nificant interaction between drug and session (F(1,107)  0.96,
p 0.33) indicated no systematic difference in temperatures ap-
plied to the 10 participants randomized to receive saline in the
first session compared with the remaining 10 who received saline
in the second session. Nevertheless, stimulus temperature was
entered as a control variable in the main LMMs of moderate
stimuli.
Intense and warm stimuli
Separate LMMs were conducted to assess potential Drug and
Session effects on VAS ratings of the non-moderate stimuli used
in the Relative Relief task (intense and warm stimuli). LMMs of
intense pain stimuli also included temperature as a fixed factor.
Pain intensity ratings of the intense pain stimulus tended to be
higher in the naloxone condition (saline, 8.0  1.9; naloxone,
8.38  1.0; F(1,277)  2.44, p  0.120; Fig. 4). Accordingly, VAS
intensity ratings of the intense pain stimulus were included in the
analysis of naloxone effects on pain downregulation of moder-
ately painful stimuli. This was done to ensure that any naloxone-
induced differences in relative relief could not be attributed to a
putative naloxone effect on the intense stimulus. Pain intensity
ratings also increased with higher temperature stimuli (F(1,277)
9.35, p  0.002). Conversely, pleasantness ratings of the intense
stimulus were nonsignificantly lower after naloxone (saline,
2.93 1.45; naloxone3.33 0.95;F(1,277) 1.92, p 0.168).
Intense stimuli were also rated as more unpleasant with increas-
ing temperatures (F(1,277)  5.06, p  0.025). Pleasantness and
intensity ratings of the warm stimuli were not significantly al-
tered by drug (intensity ratings: saline, 0.51  0.77; naloxone,
0.58  0.95; pleasantness ratings: saline, 3.21  1.53; naloxone,
2.50 1.92, F values3.3.1, p values0.072).
Main analyses
Stimulus pleasantness ratings reveal differing opioid dependence
across the pain modulation tasks
The LMM on pleasantness ratings of moderately painful stimuli
was conducted with the fixed factors Drug, Session, Task type
(Imagery or Relative Relief), Stimulus type (target or comparison
moderate heat stimulus), two-way interactions between these,
and the three-way interaction of Drug 	 Task type 	 Stimulus
type. Gender and the interaction between Gender and Stimulus type
were included in the final LMM (Table 1). Stimulus Temperature
and VASIntensity did not reach significance and did not alter the
pattern of results, with the exception that the main effect of Drug was
no longer significant when VASIntensity was included.
Main effects and interactions. Significant main effects of Drug
(F(1,1108) 4.5, p 0.035) and Stimulus type (F(1,1100) 269.9,
p  0.001) on pleasantness ratings of heat stimuli calibrated to
induce moderate pain, were qualified by significant interactions
between Task type and Stimulus type (F(1,1100)  266.1, p 
0.001), Task type, and Drug (F(1,1100) 5.8, p 0.016), Stimulus
type and Drug (F(1,1100)  6.2, p  0.013) and between Drug,
Task type, and Stimulus type (F(1,1100)  4.4, p  0.036). The
basis for these statistics is described in more detail below. There
was also a main effect of Gender (F(1,1100) 10.2, p 0.001) and
a significant interaction between Gender and Stimulus type
(F(1,1100)  16.0, p  0.001), reflecting greater pleasantness rat-
ings during target stimuli in female participants.
Mental imagery task. In the saline condition, participants were
able to use pleasant imagery to shift pleasantness ratings of mod-
erate heat stimuli from mildly unpleasant (1.0 1.1) to mod-
erately pleasant (1.81 1.49; t16.6, p 0.001; Fig. 3A, right)
on a scale where 5 indicated highly unpleasant and 5 indi-
cated highly pleasant. As hypothesized, blocking endogenous
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opioid signaling with naloxone did not significantly reduce mod-
ulation of stimulus pleasantness in the imagery task (comparison
stimulus:1.2 1.1; target stimulus: 1.57 1.16; t16.2, p
0.001). The modulation of stimulus pleasantness in the imagery
task was robust (2-point shift on 11-point VAS) and signifi-
cantly stronger than the modulation elicited in the relative relief
task, as indicated by the significant two-way interaction between
Task and Stimulus type.
Relative relief task. In the saline condition, the relative relief
task nevertheless induced a small, but statistically significant pos-
itive modulation of stimulus pleasantness ratings (target: 0.75
1.8; comparison stimulus: 0.35 1.80; t2.4, p 0.017; Fig.
3A, left). This modulation was blocked in the naloxone condi-
tion, where the target stimulus was rated as less pleasant
(0.33 1.73) than the comparison stimulus (0.03 1. 98; t
2.2, p 0.029). The average pleasantness ratings of the compar-
ison stimulus in the Relative Relief task were unexpectedly posi-
tive (i.e., consistent with mild pleasure); an inspection of
individual mean ratings indicated that half of the participants
rated the comparison stimulus as unpleasant, and the other half
as pleasant. Overall, the data from the saline condition replicates
earlier findings (Leknes et al., 2013a) with a smaller effect size
than in the original study. This could relate to inaccurate effect
size estimation with modest sample sizes, or the use of different
rating scales. Whereas Leknes et al. (2013a) showed a positive
shift of 2.2 points on an 11-point scale from painful to pleasant,
the present study used separate rating scales for pleasantness and
pain intensity.
Comparison of modulations by task. As indicated by the signif-
icant three-way interaction, naloxone treatment differentially af-
fected the modulation of stimulus pleasantness induced by the
two tasks. In other words, whereas successful upregulation of pleas-
antness was seen for stimuli calibrated to elicit moderate pain during
saline in both tasks, this regulation effect was intact after naloxone
for the imagery task but not for the relative relief task.
Pain intensity ratings consistent with differing opioid dependence
across the pain modulation tasks
After model selection, the final LMM on pain intensity ratings of
moderately painful stimuli included the fixed factors Drug, Ses-
sion, Task type, and their interactions Participant Gender, Trial
number, and VASIntensity (Table 2). Session and Stimulus Tem-
perature were not found to contribute significantly to the model.
A significant main effect of Stimulus type (F(1,1104) 146.9, p
0.001) was qualified by a significant interaction between Task
type and Stimulus type (F(1,1104) 63.9, p 0.001). Trial num-
ber, pain intensity ratings of the intense heat stimulus, and Gen-
der also significantly affected pain intensity ratings of the
moderate heat stimuli. As with the pleasantness ratings, females
showed significantly lower pain intensity ratings overall. Al-
though the overall pattern of results was consistent with our hypoth-
esis and the results for the pleasantness ratings, the three-way
interaction between Drug, Task type, and Stimulus type was not
significant for pain intensity ratings (F(1,1104) 1.9, p 0.167).
Mental imagery task. In both the saline and naloxone condi-
tions, participants were able to use pleasant imagery to signifi-
cantly and robustly reduce pain intensity ratings (saline:
comparison stimulus, 4.96 1.7; target stimulus, 2.9 1.5; t
10.2, p 0.001; naloxone: comparison stimulus, 5.1 1.8; target,
3.1 1.2; t 9.9, p 0.001; Fig. 3A, right). As with pleasantness
Figure 3. Overview of pleasantness and pain intensity ratings for moderate heat stimuli in the two pain modulation tasks. A, As hypothesized, we observed a significant three-way interaction
between Drug, Task type, and Stimulus type for pleasantness ratings. This reflected a significant reduction in pain pleasantness for the target stimulus in the relative relief task during naloxone. In
contrast, participants’ ability to use mental imagery to upregulate pain pleasantness was not reduced in the naloxone condition. We also observed significant two-way interactions between Drug,
Task type and Stimulus type, aswell as significantmain effects of Drug and Stimulus type.B, Individualmean difference scores (comparison target VAS pleasantness) for each task and each drug
condition are included for illustration purposes. C, A similar pattern of results was found for ratings of pain intensity ratings. Although the three-way interaction did not reach significance, naloxone
completely blocked the analgesic effect of the relative relief manipulation, yet did not significantly alter the analgesia induced by pleasantmental imagery.We also observed a significant two-way
interactionbetweenTask andStimulus type, anda significantmain effect of stimulus type.D, Individualmeandifference scores (comparison target VASpain intensity) for each task andeachdrug
condition are included for illustration purposes. Error bars are within-subject SEM. *p 0.05, ***p 0.001.
9052 • J. Neurosci., October 17, 2018 • 38(42):9047–9058 Berna, Leknes et al. • Opioid (In)/Dependence of Pain Modulations
ratings, imagery-induced regulation of pain intensity was robust
(2 points/30% reduction in pain scores) and significantly
stronger than the effect elicited in the relative relief task.
Relative relief task. Naloxone treatment significantly affected
the relative relief-related downregulation of pain intensity. In the
saline condition, mean pain intensity ratings decreased from
4.2  1.86 to 3.5  1.80 for the target stimulus (t  3.6, p 
0.001). For naloxone, no such decrease was observed (saline,
4.3 1.73; naloxone, 4.4 1.98; t 0.51, p 0.61).
Comparison of modulations by task. Contrary to the main hy-
pothesis, we found no significant three-way interaction effect for
pain intensity ratings, although the pattern of results was largely
consistent with that observed for pleasantness ratings. Successful
downregulation of pain intensity was seen for stimuli calibrated
to elicit moderate pain during saline in both tasks. This regula-
tion effect was intact after naloxone for the imagery task but not
for the relative relief task.
Debriefing data
Post-run ratings
An LMM conducted on ratings of anxiety elicited by each pre-
heat pain visual cue (collected at the end of each run) with the
fixed factors Drug, Task, StimType, and their interactions, as well
as Sex and Session, showed the expected interaction between
Task and StimType (F(1,150) 53.6, p 0.001), reflecting higher
mean stimulus-related anxiety for the comparison stimulus in
the mental imagery task (noxious imagery, 2.6; pleasant imagery,
1.4), whereas the target stimulus was associated with higher anx-
iety in the relative relief task (Intense run moderate, 3.8; Warm
run moderate, 1.3). There was no evidence for an interaction with
naloxone on these effects (F(1,150)  0.05, p  0.8; Fig. 4B).
Stimulus-related anxiety was somewhat higher in Session 1
(F(1,150)  6.4, p  0.013), but naloxone treatment did not sig-
nificantly interact with session or other factors to influence these
ratings.
The LMM on post-run ratings of relief intensity experienced
during presentation of the relative relief cue (with Drug, Session,
and Gender as fixed factors) revealed comparable relief across
drug conditions (saline, 4.6; naloxone, 5.3; F(1,36)  1.0, p 
0.32). Ratings of disappointment at the presentation of the com-
parison cue (upward pointing arrows in the warm run) also
showed no significant modulation by drug condition, session, or
participant gender (all F values1.0; p values0.32).
Analysis of self-reported success of mental imagery during
pain revealed somewhat higher ratings for the pleasant compared
with the noxious imagery condition (pleasant, 7.3; noxious, 6.8;
F(1,74) 5.5, p 0.022). Self-reported effort during the imagery
Table 1. Basic and final LMMs for stimulus pleasantness
Model 1 Final model
VAS pleasantness Bayesian information criterion: 4102.75 Bayesian information criterion: 4081.13
Fixed effects F df1 df2 Sig F df1 df2 Sig
Corrected model 80.744 7 1112 0.000 66.362 9 1110 0.000
Task 0.114 1 1112 0.736 0.128 1 1110 0.721
Stimulus 282.091 1 1112 0.000 269.806 1 1110 0.000
Drug 4.468 1 1112 0.035 5.016 1 1110 0.025
Task	 Stimulus 262.400 1 1112 0.000 266.014 1 1110 0.000
Task	 Drug 5.699 1 1112 0.017 5.777 1 1110 0.016
Stimulus	 Drug 6.071 1 1112 0.014 6.155 1 1110 0.013
Task	 Stimulus	 Drug 4.363 1 1112 0.037 4.423 1 1110 0.036
Gender — — — — 7.740 1 1110 0.005
Gender	 Stimulus — — — — 16.025 1 1110 0.000
Estimates of covariance parameters Estimate SE Z Sig Estimate SE Z Sig
Residual 1.965 0.086 22.969 0.000 1.939 0.084 22.947 0.000
Intercept participant 0.483 0.100 4.828 0.000 0.424 0.090 4.681 0.000
Estimated means Mean SE 95% CI 95% CI Mean SE 95% CI 95% CI
Saline
Comparison 0.914 0.294 1.491 0.337 0.956 0.279 1.504 0.409
Target 1.881 0.294 1.304 2.458 1.806 0.279 1.259 2.353
Mental Imagery
Comparison 0.389 0.294 0.188 0.966 0.347 0.279 0.201 0.894
Target 0.820 0.294 0.243 1.397 0.745 0.279 0.197 1.292
Relative Relief
Comparison 1.180 0.294 1.757 0.603 1.222 0.279 1.769 0.675
Target 1.553 0.294 0.976 2.130 1.477 0.279 0.930 2.025
Mental Imagery
Comparison 0.073 0.294 0.504 0.650 0.031 0.279 0.517 0.578
Target 0.259 0.294 0.836 0.318 0.334 0.279 0.881 0.213
Relative Relief
Women — — — — 0.824 0.283 0.268 1.379
Men — — — — 0.350 0.313 0.965 0.264
Women
Comparison — — — — 0.031 0.289 0.597 0.536
Target — — — — 1.678 0.289 1.112 2.244
Men
Comparison — — — — 0.870 0.319 1.496 0.244
Target — — — — 0.169 0.319 0.457 0.795
Sig, Significance.
Berna, Leknes et al. • Opioid (In)/Dependence of Pain Modulations J. Neurosci., October 17, 2018 • 38(42):9047–9058 • 9053
task was comparable across stimulus types and drug conditions
(pleasant, 4.1; noxious, 4.5). No other factors or interactions sig-
nificantly influenced self-reported imagery success or effort ex-
erted during the mental imagery task (all F values1.4; p values
0.24).
Manipulation check
The mean estimated probability of the intense stimulus was 66
9% (i.e., vs 34% moderate) for the Intense run and at 64 12%
for the warm stimulus (i.e., vs 36% moderate) in the Warm run.
In contrast, participants correctly estimated the probability of
each of the conditions in the mental imagery task to 50% ( 6%).
The target stimulus occurred in 50% of cases across all three runs.
Hence, the deceptive suggestion used to boost the relative relief
effect, i.e., that the intense and warm stimuli would be the most
frequently occurring stimuli in the respective runs, was seen to
influence the estimation of stimulus probability.
Naloxone side effects
Of note, three participants reported intense nausea after the first
session and did not return for a second session. They attributed
the symptoms to naloxone. Unblinding confirmed that they had
indeed received naloxone. These participants were excluded from
analysis given the incomplete data. Although the frequency of
reported side effects in the study completers (N 20) was some-
what higher for the naloxone condition, only the reports of nau-
sea occurred significantly more frequently after naloxone (Table
3). When considering the severity of the symptoms (categorized
on a numerical scale anchored at “very weak” to “extremely
strong”), no symptom was categorized as5 (strong). The com-
parison of the scores between groups revealed significantly
higher ratings in the naloxone group for nausea and dry
mouth (Table 3).
Scores on the Bond–Lader scale did not show any significant
differences between the naloxone and saline session on any of the
four axes (mental sedation, tranquility, physical sedation, socia-
bility; all p values0.5).
Drug blinding
Despite these differences in side effects, blinding was maintained
during the testing sessions. When asked to guess which drug they
received immediately after each of the testing sessions, partici-
pants were at chance level, i.e., drug attribution was 50% correct.
Table 2. Basic and final LMMs for pain intensity
Model 1 Final model
VAS pain intensity Bayesian information criterion: 4479.39 Bayesian information criterion: 4461.83
Fixed effects F df1 df2 Sig F df1 df2 Sig
Corrected model 31.399 7 1112 0.000 17.000 15 1104 0.000
Corrected model 0.220 1 1112 0.639 0.270 1 1104 0.603
Task 145.528 1 1112 0.000 146.987 1 1104 0.000
Stimulus 3.285 1 1112 0.070 1.114 1 1104 0.291
Drug 63.320 1 1112 0.000 63.955 1 1104 0.000
Task	 Stimulus 2.620 1 1112 0.106 2.647 1 1104 0.104
Task	 Drug 2.931 1 1112 0.087 2.961 1 1104 0.086
Stimulus	 Drug 1.890 1 1112 0.170 1.909 1 1104 0.167
Gender — — — — 4.941 1 1104 0.026
Trial — — — — 2.877 6 1104 0.009
VASintense — — — — 7.883 1 1104 0.005
Estimates of covariance parameters Estimate SE Z Sig Estimate SE Z Sig
Residual 2.772 0.121 22.991 0.000 2.745 0.120 22.91 0.000
Intercept participant 0.608 0.125 4.865 0.000 0.477 0.104 4.59 0.000
Estimated means Mean SE 95% CI 95% CI Mean SE 95% CI 95% CI
Saline
comparison 4.810 0.333 4.156 5.464 4.969 0.305 4.370 5.567
target 2.784 0.333 2.131 3.438 2.943 0.305 2.345 3.541
Mental Imagery
comparison 4.119 0.333 3.465 4.772 4.277 0.305 3.679 4.875
target 3.403 0.333 2.749 4.056 3.561 0.305 2.963 4.160
Relative Relief
Naloxone
Mental Imagery
comparison 5.097 0.333 4.444 5.751 5.040 0.306 4.440 5.640
target 3.139 0.333 2.485 3.792 3.081 0.306 2.481 3.681
Relative Relief
comparison 4.454 0.333 3.801 5.108 4.397 0.306 3.797 4.997
arget 4.353 0.333 3.699 5.006 4.296 0.306 3.696 4.895
Women — — — — 3.564 0.304 2.969 4.160
Men — — — — 4.576 0.336 3.917 5.236
Trial 1 — — — — 4.174 0.256 3.673 4.676
Trial 2 — — — — 4.201 0.256 3.699 4.702
Trial 3 — — — — 4.354 0.256 3.853 4.856
Trial 4 — — — — 4.073 0.256 3.571 4.575
Trial 5 — — — — 3.939 0.256 3.438 4.441
Trial 6 — — — — 3.658 0.256 3.156 4.160
Trial 7 — — — — 4.093 0.256 3.591 4.595
Final Model: Continuous predictors are fixed at the following values: VASintense 8.187
Sig, Significance.
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Discussion
This study used a double-blind, placebo-controlled intravenous
naloxone versus saline crossover design to test the opioid-
reliance of two novel pain modulation tasks. In the saline condi-
tion, both the pleasant imagery (reappraisal) and relative relief
(context/expectation) modulations significantly reduced pain
intensity ratings and increased the reported pleasantness of a
stimulus calibrated as moderately painful. Indeed, both target
heat-pain stimuli in the imagery and relative relief tasks were
rated as mildly pleasant. Furthermore, in accordance with the
main hypothesis, blocking endogenous opioid signaling with nal-
oxone did not significantly affect imagery-induced regulation of
pain intensity or unpleasantness. Yet, as indicated by a significant
three-way interaction between task, stimulus type, and drug, nal-
oxone blocked the relative relief-induced pain modulation.
Whereas prior naloxone studies have investigated pain modula-
tions, a strength of the current approach lies in contrasting two
novel techniques with an a priori hypothesis of opioid reliance
versus independence.
In the saline condition, we replicate our previous finding that
in a relative relief task, heat stimuli calibrated to induce moderate
pain can elicit a positive affect (Leknes et al., 2013a) and show a
corresponding decrease in pain intensity ratings. The mean im-
provement across these VASs was smaller than in our original
paper, possibly reflecting minor differences in design and mea-
surements. Self-reported relative relief-related effects have been
supported by altered ventromedial prefrontal activity (Leknes et
al., 2013a; Winston et al., 2014), and by monetary worth of avoid-
ing moderately painful stimuli in the context of intense pain
(compared with a low-pain context; Winston et al., 2014). The
relative relief modulation relies on fully predictive visual cues
informing participants that the stimulus will be less hot. In the
absence of such cues, moderate stimuli are often perceived as
more painful in a context of intense pain (Koyama et al., 2005;
Keltner et al., 2006; Atlas et al., 2010). Perception of noisy or
ambiguous stimuli such as experimental heat is heavily guided by
the brain’s prediction models (Johnston et al., 2012; Bu¨chel et al.,
2014; Tabor et al., 2017) and priors (Wiech et al., 2014b). For
instance, expecting pain will increase the likelihood of interpret-
ing an ambiguous sensory stimulus as painful (Taylor et al.,
2017). Here, debriefing indeed confirmed that participants be-
lieved that the most likely outcome of the Intense run was intense
pain. Hence, a fully predictive, unambiguous cue indicating the
occurrence of a lower temperature stimulus interrupted the ex-
pectation of intense pain, updating the prediction about the ac-
tual stimulus.
Surprise enhances emotions (Mellers and Ritov, 2010). In-
spired by our prior finding that dispositional pessimists reported
more relief in response to an unambiguous, fully predictive relief
cue (Leknes et al., 2011), we speculate that the relative relief effect
relies on how predictive (i.e., certain) the intense pain and rela-
tive relief cues are perceived to be. Because the majority of
placebo-induced expectation studies point to a major role for the
-opioid system, and due to our prior finding that the relative
relief manipulation increased positive affect and PAG activity, we
hypothesized that the relative relief effect would rely on endoge-
nous opioid signaling. The present observations that naloxone
blocked the relative relief improvement in pain pleasantness and
intensity ratings confirmed this hypothesis.
In the mental imagery task, participants successfully increased
the perceived pleasantness and decreased the pain intensity of the
stimulus compared with the control task, independently of nal-
oxone treatment. The task was based on mental imagery used in
clinical pain management (Winterowd et al., 2003; Pincus and
Sheikh, 2009; Posadzki and Ernst, 2011; Posadzki et al., 2012).
Notably, the task induced a large and clinically significant mod-
ulation (i.e.,30% reduction of pain intensity ratings; Farrar et
al., 2001) of heat pain in healthy volunteers, regardless of drug
condition. The modulation of pain pleasantness was equally ro-
bust and naloxone-independent, with a shift in perception into
the positive affective domain. Participants quickly mastered the
task, and reported exerting only moderate effort during both
mental imagery conditions.
Our results showing the opioid independence of mental
imagery-induced pain relief confirm prior untested hypotheses
that such pain modulation may not rely on the descending inhib-
Figure4. Overviewof secondary outcomes.A, VAS ratings of pleasantness and intensity for the intenseheat andwarmstimuli. A trend towardhigher pain intensity ratings of the intense stimulus
in the naloxone condition led to the inclusion of these ratings as a confound regressor in the analysis of the ratings of the target and comparison stimuli. B, Ratings of other relevant aspects of the
taskswere collected via verbal, 11-pointNRSs after each run. Post-run ratings of cue-related anxiety formoderate pain stimuli (target and comparison) in both tasks revealed a significant interaction
between Task and Stimulus type, but no significant differences between Drug conditions. Post-run ratings of the effort that was exerted during mental imagery similarly did not reveal any effects
of naloxone nor of type of imagery. Post-run ratings of relief (0–10NRS scale after Intense run) or disappointment (0–10NRS scale afterWarm run) elicited by the delivery of themoderate stimulus
revealed no significant effect of naloxone. Error bars are SEM.
Table 3. Side-effect reports
Saline Naloxone Significance
N Rating M (SD) N Rating M (SD) N Ratings
Dry mouth 7 1.35 (0.49) 9 1.90 (1.17) 0.52 0.02*
Dry skin 2 1.10 (0.31) 3 1.30 (0.80) 0.63 0.26
Blurred vision 3 1.25 (0.72) 7 1.60 (0.88) 0.14 0.07
Sedation 10 1.85 (0.99) 14 2.35 (1.27) 0.20 0.10
Nausea 1 1.10 (0.45) 7 1.60 (0.94) 0.02* 0.02*
Dizziness 9 1.75 (0.97) 11 2.10 (1.25) 0.53 0.17
Headache 6 1.45 (0.83) 8 1.60 (0.88) 0.51 0.33
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itory system. Ruscheweyh et al. (2011) reported that positive im-
agery left the RIII reflex (a measure of spinal nociception)
unaltered. The neural underpinnings of mental imagery are little
known (Jensen et al., 2012; Fardo et al., 2015). A likely underlying
psychological mechanism is reappraisal. Reappraisal involves
giving a new interpretation to an emotional or painful stimulus
(Wiech et al., 2008b). Reappraisal is proposed to be driven by
prefrontal cognitive control regions, followed by lateral temporal
cortex activation and subsequent amygdala inhibition (Buhle et
al., 2014). Repeated associations of a noxious input with a more
positive meaning could also facilitate new associative learning. A
heightened sense of control could also be at play, underpinned by
increased ventrolateral prefrontal cortex and nucleus accumbens
activity (Wiech et al., 2006, 2014a) and decreased amygdala acti-
vation (Salomons et al., 2015). Furthermore, positive imagery
could raise other emotional processes such as enhanced mood, a
more positive bias, or increased appetite for rewards (Linke and
Wessa, 2017). At the neurochemical level, initial findings point
to endocannabinoid signaling as the driving factor of both
opioid-independent analgesia (Benedetti et al., 2011) and
long-term associative learning (Schafer et al., 2018). Another
study highlighted the contribution of endocannabinoids to
reward processing in the ventral striatum (Horder et al.,
2010). We therefore speculate that mental imagery analgesia
may rely on activity in prefrontal-accumbens/amygdala cir-
cuits and could be endocannabinoid-dependent.
The present findings add to the literature on opioid-
dependent and opioid-independent pain modulations. With the
exception of placebo analgesia, which is reduced by naloxone and
naltrexone in most published studies (Amanzio and Benedetti,
1999; Benedetti et al., 1999, 2007; Eippert et al., 2009; Ru¨tgen et
al., 2015, 2017), knowledge on the opioid dependence of pain
modulations is limited by a lack of replication studies and incon-
sistent drug administration methods (Werner et al., 2015). In
light of mounting evidence of endogenous opioid involvement in
reward processing in rodents (Cooper and Turkish, 1989; Mahler
and Berridge, 2009; Berridge and Kringelbach, 2015) and hu-
mans (Chelnokova et al., 2016; Eikemo et al., 2016, 2017; Weber
et al., 2016), it is noteworthy that with the help of mental imagery,
participants reported large shifts in their affective evaluation of
pain (into the reward domain) even with their-opioid receptors
blocked. Previous studies of the opioid reliance of reward-related
analgesia in humans provided mixed results (Kut et al., 2011;
Benedetti et al., 2013). Together, these findings may indicate that
factors other than the affective value, such as expectations or the
degree of voluntary regulation, could determine how much a
pain modulation depend on opioid signaling.
Some potential limitations warrant consideration. Consistent
with prior research, naloxone treatment at a sufficient dose for
complete blockade of -opioid receptors (Mayberg and Frost,
1990) did not cause significant mood changes. Indeed, despite
fewer side effects in the saline condition, drug blinding was full at
the end of each experimental session. Three-way interaction tests
assessed the main hypothesis of the study, i.e., that analgesia in
the relative relief but not mental imagery task would be blocked
by naloxone. Although previous studies using naloxone to block
placebo analgesia indicated large effect sizes (Levine et al., 1978;
Amanzio and Benedetti, 1999), our within-subjects sample size of
20 people limits the generalizability of the results. Indeed, while
the pattern of results was consistent with the main hypothesis for
both pleasantness and pain intensity ratings, the hypothesized
interaction was statistically supported only for pleasantness rat-
ings. Future studies should replicate, in larger samples, these and
other key findings in the literature on the opioid dependence of
pain modulations.
The pain modulation by mental imagery was significantly
larger than by relative relief, consistent with prior findings of
voluntary reappraisal profoundly altering responses to affective
stimuli (Moret et al., 1991; Wager et al., 2008; Woo et al., 2015).
The pain intensity and unpleasantness ratings of the comparison
stimulus were significantly higher in the mental imagery than the
relative relief task. This difference could be due to hyperalgesia
induced by the noxious comparison imagery (Fardo et al., 2015),
and/or to hypoalgesia given the reduced likelihood of pain in the
Warm run (Taylor et al., 2017). Indeed, unexpectedly the relative
relief task comparison stimulus was not consistently rated as un-
pleasant, despite a mean pain intensity score of 4/10. The mod-
erate heat stimuli were delivered through two thermodes in the
mental imagery task, compared with one in the relative relief task.
This could also play a role. The contribution of these factors
cannot be disentangled here, but have little bearing on the main
results of the study as the target stimulus of each task had its own
comparator.
In conclusion, this comparison of the effects of naloxone on
two reward-oriented pain modulations suggests that relative re-
lief is an opioid-dependent process, whereas mental imagery is
opioid-independent. Mental imagery provides a useful therapeu-
tic approach in the chronic pain state. Implemented here to mod-
ulate acute experimental pain, it had powerful effects and was
easy to instruct to participants. Mental imagery might ultimately
favor positive appraisals (Linke and Wessa, 2017), which are cen-
tral to resilience (Kalisch et al., 2015). Clinically, tapping into
opioid-independent pain modulatory mechanisms is very rele-
vant as a complement to pharmacological therapy. It could be
especially interesting in patients treated with long term opioids,
as they might have alterations in emotion regulation processes
(Garland et al., 2017a,b), or those where the opioidergic function
may be disrupted, whether due to mood disorders (Hsu et al.,
2015) or chronic pain itself (Harris et al., 2007; Martikainen et al.,
2013).
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